Elevations in breast cancer mortality risks were observed among women with ER+/PR-, ER-/PR+, and ER-/PR- tumors relative to women with ER+/PR+ tumors across the majority of clinical characteristics examined (Table 2). This evidence concerns the gene PGR and breast cancer.